News
What's happening in Alzheimer's care, research funding, and treatment — summarized simply, each item linked to the original reporting.
Free to read, “May need a subscription” and “Archived copy”: what they mean
Whether an article is free to read is a guess, not a test of your access. Each item is one of three:
- No label: free to read (311 of 358). The publisher’s page marks it free, or the outlet publishes free to read: Medical Xpress, ScienceDaily, NIH (incl. NIA and PMC), Alzheimer's Association, Alzheimer's News Today, NPR, Alzheimer's Disease International, or a .gov site.
- May need a subscription (12 of 358). The publisher’s own page marks the article as not free to read, or — when the page says nothing — the outlet sells subscriptions: The New York Times, STAT, Scientific American, The Washington Post, The Wall Street Journal, Financial Times, The Economist, Bloomberg, The Atlantic, The New Yorker, Wired, Los Angeles Times, The Boston Globe, The Times, The Telegraph, New Scientist, Endpoints News, Science. Each badge says which.
- “Free to read? Not known” (35 of 358). The outlet is on neither list and its page said nothing. We do not call these paywalled.
Archived copy links go to a copy the Internet Archive (web.archive.org) saved, dated the day it was saved. We show one only where the Internet Archive reported a working saved copy when we checked; an archived copy of a subscription article sometimes shows only its opening. 266 of 358 items have one.
Scientists discover new Alzheimer’s drug that repairs DNA damage and reduces brain inflammation
Scientists have discovered that a drug originally developed for spinal cord injuries can tackle several key features of Alzheimer’s disease, including DNA damage and inflammation. …
Read at ScienceDaily →Treatment revives old liver cells in lab study, may help prevent Alzheimer's and heart disease
The liver's job of clearing harmful substances from the body is so essential that the organ may have implications for addressing unexpected diseases, including Alzheimer's and heart disease. …
Read at Medical Xpress →Experimental treatment selectively reduces harmful protein in lab models of rare inherited brain disorder
Researchers from DZNE and the Hertie Institute for Clinical Brain Research (HIH) at the University of Tübingen, together with experts from Bonn, London and Portugal…
Read at Medical Xpress →Who gets Alzheimer's drugs? Race, vulnerability and health status shape access
The first disease-modifying drugs for Alzheimer's disease offer patients the ability to slow cognitive decline by targeting amyloid plaques in the brain. But a new study suggests that not all patients have the same opportunity to receive these treatments.
Alzheimer's Drug ARIA Monitoring: Real-World Study Results
(MedPage Today) -- Rates of amyloid-related imaging abnormalities (ARIA) in Alzheimer's disease patients treated with lecanemab (Leqembi) in the real world were consistent with those seen in clinical trials, data from the LEADER study showed....
Free to read? Not known for this outlet.
Read at MedPage Today → Archived copy (17 Oct 2026), Internet ArchiveDrug combination that reduces oxygen levels in tissues improves Parkinson's symptoms in mice
In a new study, Broad Institute researchers report that two small-molecule chemicals that reduce oxygen delivery to cells improved symptoms of neurodegeneration in a mouse model of Parkinson's disease. …
Read at Medical Xpress →The hidden math of Alzheimer's could point to new treatments
Mathematics may hold unexpected clues to understanding Alzheimer’s disease. Scientists have developed a model showing how common metals like copper and zinc may influence the buildup of proteins associated with the disease, while also exploring possible ways to stop…
Read at ScienceDaily → Archived copy (12 Oct 2026), Internet ArchiveClinical trial tests AI-assisted medication device for older adults with memory loss
Marianne Blake has lived in the same home for nearly half a century. She plays bridge regularly, drives to her hair appointments and, at 88 years old, enjoys her independence.
Read at Medical Xpress →Can hormone replacement therapy prevent dementia? What the latest research tells us
A study has raised a question that many women would understandably want answered: Could hormone replacement therapy (HRT) protect against dementia? …
Why it matters: A study raised a key question about whether hormone replacement therapy (HRT) could help protect women against dementia.
Read at Medical Xpress →Blood proteins shift during Alzheimer's treatment and may help monitor the effects of the medication
Patients with early symptoms of Alzheimer's disease may be prescribed anti-amyloid therapy, which can help clear the sticky clumps of amyloid protein in the brain that characterize Alzheimer's. …
Why it matters: Shifts in blood proteins during Alzheimer's treatment may help monitor the effects of medication in patients receiving anti-amyloid therapy.
New Alzheimer's drug repairs DNA damage and reduces brain inflammation
A drug originally developed for spinal cord injury may offer a fresh approach to treating Alzheimer’s disease. In mouse studies, KCL-286 repaired dangerous DNA damage, reduced inflammation…
Read at ScienceDaily → Archived copy (17 Jul 2026), Internet ArchiveScientists reprogram brain immune cells to fight Alzheimer’s
A newly identified molecule called OLE helped restore the brain’s immune cells to a more protective state in Alzheimer’s models. The treatment reduced toxic plaque buildup and improved memory, raising hopes for a new therapeutic approach.
Read at ScienceDaily →Scientists found a new Alzheimer’s trigger and a drug that stops it
Researchers have identified a new Alzheimer’s target and created an experimental compound that blocks a damaging process inside brain cells. In mice, the treatment slowed nerve cell loss, reduced Alzheimer’s-related changes, and even appeared to promote healthier aging.
Read at ScienceDaily → Archived copy (23 Sep 2026), Internet ArchiveScientists say we’ve been treating Alzheimer’s all wrong
Alzheimer’s isn’t just one problem—it’s a tangled mix of biology, aging, and overall health. That’s why drugs targeting a single factor have fallen short, even as new treatments show modest benefits. …
Read at ScienceDaily → Archived copy (23 Sep 2026), Internet ArchiveScientists finally reveal how this Alzheimer’s drug really works
A key Alzheimer’s drug has finally revealed its secret. Researchers discovered that lecanemab works by activating the brain’s immune cells—but only through a specific part of the antibody called the Fc fragment. …
Researchers explore surgical treatment’s potential in Alzheimer’s
Researchers are calling for more studies to determine whether lymphovenous anastomosis (LVA), a surgical procedure that helps clear molecular waste from the brain, might benefit people with Alzheimer’s disease. …
Read at Alzheimer's News Today → Archived copy (1 Jul 2026), Internet ArchiveSeniors with dementia being prescribed dangerous mind-altering drugs, study says
Many seniors with dementia are being put at risk by brain-altering medications linked to falls, confusion and hospitalization, a new study says.
Why it matters: Many seniors with dementia are put at risk by brain-altering medications linked to falls, confusion, and hospitalization, according to a new study.
Read at Medical Xpress → Archived copy (17 Jan 2026), Internet ArchiveSafe, low-cost Alzheimer's drug demonstrates efficacy against sickle cell anemia
Memantine, a long-approved and cost-effective drug used to treat Alzheimer's disease, could also benefit patients with sickle cell anemia in the future. …
Why it matters: Memantine, a long-approved and cost-effective Alzheimer's drug, shows potential to benefit patients with sickle cell anemia in the future.
Read at Medical Xpress →New ALS treatment target identified: STAUFEN-1 protein reduction protects brain cells from death
University of Utah researchers at the Pulst-Scoles Laboratory have discovered that reducing levels of the STAUFEN-1 protein can prevent neuron death caused by DNA damage and p53 activation in neurodegenerative diseases.
Why it matters: Reducing STAUFEN-1 protein levels can prevent neuron death caused by DNA damage and p53 activation in neurodegenerative diseases like ALS.
Read at Medical Xpress →Key phospholipid points to potential treatment for vascular dementia
A possible new treatment for impaired brain blood flow and related dementias is on the horizon. Research by scientists at the University of Vermont Robert Larner…
Why it matters: Research by scientists at the University of Vermont Robert Larner points to a potential treatment for impaired brain blood flow and vascular dementia.
Read at Medical Xpress → Archived copy (3 Jan 2026), Internet ArchiveMiddle-aged brains show capacity for repair when treated with therapeutic intervention
Normal aging is characterized by deficits in the cognitive domains of learning, memory and executive function. Specifically, there are age-related changes in recall of information, speed of processing, visuospatial skills and cognitive flexibility. …
Why it matters: Normal aging brings cognitive deficits in learning, memory, and executive function, but middle-aged brains demonstrate a capacity for repair when treated with therapeutic intervention.
Read at Medical Xpress → Archived copy (29 Dec 2025), Internet ArchivePill form of semaglutide fails to slow Alzheimer's in large trial
A pill version of semaglutide, the ingredient in Ozempic and Wegovy, did not slow the progress of Alzheimer's disease, drugmaker Novo Nordisk announced on Nov. 24.
Why it matters: A pill form of semaglutide failed to slow Alzheimer's disease progression in a large trial, Novo Nordisk announced on Nov. 24.
Read at Medical Xpress → Archived copy (6 Jan 2026), Internet ArchiveNovel discovery reveals how brain protein OTULIN controls tau expression and could transform Alzheimer's treatment
Scientists have uncovered a surprising mechanism by which a brain enzyme called OTULIN controls the expression of tau, the protein that forms toxic tangles in Alzheimer's disease. …
Why it matters: Scientists uncovered a surprising mechanism by which the brain enzyme OTULIN controls tau expression, which could transform Alzheimer's treatment.
Read at Medical Xpress → Archived copy (25 Nov 2025), Internet ArchiveAlzheimer's Association Statement on Oral Semaglutide Phase 3 Topline Data Release
Novo Nordisk's EVOKE and EVOKE+ Phase 3 trials of oral semaglutide in more than 3,800 people with early symptomatic Alzheimer's did not meet the primary endpoint of significantly slowing disease progression, despite improving some Alzheimer's-related biomarkers. Novo Nordisk ended its Alzheimer's trials for semaglutide, including the injectable version.
Why it matters: A high-profile failure for the theory that GLP-1 weight-loss drugs could treat Alzheimer's, dampening near-term hopes for repurposing this popular drug class for dementia.
Read at Alzheimer's Association → Archived copy (30 Jul 2026), Internet ArchiveJ&J's Novel Alzheimer's Drug Fails in Key Trial, Dimming Hopes for a Hot Target
Johnson & Johnson terminated its mid-stage trial of posdinemab, a tau-targeting antibody, after an early analysis showed it was not outperforming placebo in slowing Alzheimer's progression.
Why it matters: A setback for the broader strategy of targeting tau protein rather than amyloid, a drug class also being pursued by Biogen, UCB, and Voyager Therapeutics.
May need a subscription Based on the outlet (STAT), not a check of this article.
Read at STAT News → Archived copy (1 Mar 2026), Internet ArchiveShingles vaccine most promising common drug to potentially prevent Alzheimer's
A new study has identified three existing medications that could be repurposed to treat or prevent Alzheimer's disease.
Why it matters: A new study identified three existing medications, including the shingles vaccine, that could be repurposed to treat or prevent Alzheimer's disease.
Read at Medical Xpress → Archived copy (19 Nov 2025), Internet ArchiveProtective microglia subtype offers potential therapeutic pathway in Alzheimer's disease
In Alzheimer's disease—the leading cause of dementia—microglia, the brain's immune defenders, can act as both protectors and aggressors, shaping how the disease progresses.
Read at Medical Xpress → Archived copy (15 Nov 2025), Internet ArchiveAlzheon's Alzheimer's Pill Fails in Phase III Trial
Alzheon's oral drug valiltramiprosate missed the primary endpoint in its 325-patient APOLLOE4 Phase 3 trial of early Alzheimer's patients with two copies of the APOE4 gene, though a prespecified mild cognitive impairment subgroup showed larger cognitive and functional benefits.
Why it matters: Another setback for a non-antibody, oral approach to Alzheimer's treatment, though the positive subgroup signal could still support a narrower regulatory path.
Free to read? Not known for this outlet.
Read at Clinical Trials Arena → Archived copy (17 Jun 2026), Internet ArchiveNew drug candidate targeting synaptic resilience well tolerated in Alzheimer’s patients
A new drug targeting synaptic resilience shows potential in treating Alzheimer’s disease in an NIA-funded study, with early trials indicating safety and possible brain damage reduction. Further research is needed on the drug’s long-term effects.
Why it matters: An NIA-funded study shows a new Alzheimer's drug candidate targeting synaptic resilience is well tolerated in early trials and may reduce brain damage.
Senolytic therapy shows subtle impact on age-related bone health in women
An NIA-funded clinical trial investigating whether senolytics could improve bone health in older women had just subtle results.
Why it matters: An NIA-funded clinical trial investigating whether senolytics could improve bone health in older women had just subtle results.
Read at NIH National Institute on Aging → Archived copy (7 Jul 2025), Internet ArchiveFollow new items in a feed reader: Atom feed.